Vimarsana
Biggest News Aggregation in the World

Page 47 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

EUSA Pharma (UK), Ltd.: BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma - Vimarsana News

EUSA Pharma (UK), Ltd.: BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma

BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has granted QARZIBA(dinutuximab beta) conditional approval

Hauptstadtregion Paris führt eigene E-Kaufprämie ein - Vimarsana News

Hauptstadtregion Paris führt eigene E-Kaufprämie ein

Der französische Hauptstadt-Gemeindeverband Métropole du Grand Paris gewährt Privatpersonen Zuschüsse in Höhe von bis zu 6.000 Euro für den Kauf von alternativ betriebenen Fahrzeugen (BEV, FCEV, PHEV,

Fierce Pharma Asia—Moderna-Samsung COVID vaccine pact; Astellas' 5-year plan; more Novo investment - Vimarsana News

Fierce Pharma Asia—Moderna-Samsung COVID vaccine pact; Astellas' 5-year plan; more Novo investment

Moderna enlisted Samsung Biologics to help with fill-finish of its mRNA COVID-19 vaccine. Astellas targeted $17 billion in fiscal 2025 sales in a new five-year plan. Novo Holdings co-led a $200 million financing round in a Singapore cell and gene therapy tech company. And more

Fierce Pharma Asia—BeiGene-Novartis PD-1 deal; Sinovac vaccine; Celltrion antibody COVID-19 data - Vimarsana News

Fierce Pharma Asia—BeiGene-Novartis PD-1 deal; Sinovac vaccine; Celltrion antibody COVID-19 data

Brazilian researchers first said Sinovac’s COVID-19 vaccine, CoronaVac, was 78% effective in a local phase 3 trial. But then, a few days ago, they released new data of just 50.4% efficacy. The gap was caused by the omission of “very mild” infections in the previous data. The misstep led to criticism of the trial organization, Brazil’s Butantan biomedical center, as well as suspicion about CoronaVac’s true efficacy. Turkey just authorized the shot for emergency use based on a reported 91.25% efficacy in an interim analysis of its local trial. Celltrion’s anti-coronavirus antibody ...

Novartis Fortifies Immuno-Oncology Franchise with BeiGene Collaboration - Vimarsana News

Novartis Fortifies Immuno-Oncology Franchise with BeiGene Collaboration

On January 11th, Novartis signed a strategic collaboration agreement to in-license tislelizumab from BeiGene in major markets outside of China